Extended Data Fig. 1: Plasma pharmacokinetics (PK) (N = 32 patients, Suppl. Table 3) and skin pharmacodynamics (PD) (N = 34 patients, Suppl. Table 4) support FX-909 is a pharmacologically active drug.
From: A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
A, Geometric mean steady-state plasma concentrations of FX-909 vs. time following single oral administrations of FX-909 on C1D15. Error bars represent geometric standard error. B, FABP4 expression measured as % change from baseline in paired skin punch biopsies, collected at screening and C1D15. 1 patient had a % change from baseline that was > 250%. The y-axis has been clipped to 100% for presentation purposes.
